Diagnosis of Glutaric Aciduria Type 1 by Measuring 3-hydroxyglutaric Acid in Dried Urine Spots by Liquid Chromatography Tandem Mass Spectrometry

Authors

Osama Y. Al-Dirbashi, Children's Hospital of Eastern Ontario, Ottawa, ON
Stefan Kölker, University Children's Hospital, Heidelberg, Germany
Dione Ng, Children's Hospital of Eastern Ontario, Ottawa, ON
Lawrence Fisher, Children's Hospital of Eastern Ontario, Ottawa, ON
Tony Rupar, The University of Western Ontario
Nathalie Lepage, University of Ottawa
Mohamed S. Rashed, Pharmagene Labs, Giza, Egypt
Tomofumi Santa, University of Tokyo, Tokyo, Japan
Stephen I. Goodman, University of Colorado
Michael T. Geraghty, Children's Hospital of Eastern Ontario, Ottawa, ON
Johannes Zschocke, Innsbruck Medical University, Innsbruck, Austria
Ernst Christensen, National University Hospital Rigshospitalet, Copenhagen, Denmark
Georg F. Hoffmann, University Children's Hospital, Heidelberg, Germany
Pranesh Chakraborty, Children's Hospital of Eastern Ontario, Ottawa, ON

Document Type

Article

Publication Date

2-2011

Journal

Journal of Inherited Metabolic Disease

Volume

34

Issue

1

First Page

173

Last Page

180

URL with Digital Object Identifier

http://dx.doi.org/10.1007/s10545-010-9223-2

Abstract

Accumulation of glutaric acid (GA) and 3-hydroxyglutaric acid (3HGA) in body fluids is the biochemical hallmark of type 1 glutaric aciduria (GA1), a disorder characterized by acute striatal degeneration and a subsequent dystonia. To date, methods for quantification of 3HGA are mainly based on stable isotope dilution gas chromatography mass spectrometry (GC-MS) and require extensive sample preparation. Here we describe a simple liquid chromatography tandem MS (LC-MS/MS) method to quantify this important metabolite in dried urine spots (DUS). This method is based on derivatization with 4-[2-(N,N-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (DAABD-AE). Derivatization was adopted to improve the chromatographic and mass spectrometric properties of the studied analytes. Derivatization was performed directly on a 3.2-mm disc of DUS as a sample without extraction. Sample mixture was heated at 60°C for 45 min, and 5 μl of the reaction solution was analyzed by LC-MS/MS. Reference ranges obtained were in excellent agreement with the literature. The method was applied retrospectively for the analysis of DUS samples from established low- and high-excreter GA1 patients as well as controls (n = 100). Comparison of results obtained versus those obtained by GC-MS was satisfactory (n = 14). In populations with a high risk of GA1, this approach will be useful as a primary screening method for high- or low-excreter variants. In these populations, however, DUS analysis should not be implemented before completing a parallel comparative study with the standard screening method (i.e., molecular testing). In addition, follow-up DUS GA and 3HGA testing of babies with elevated dried blood spot C5DC acylcarnitines will be useful as a first-tier diagnostic test, thus reducing the number of cases requiring enzymatic and molecular analyses to establish or refute the diagnosis of GA1.